Amgen

-8.01%

1. Regulatory Risks: Amgen must comply with numerous laws and regulations to continue operating. Changes in laws and regulations, such as those related to patent protection or pricing laws, could adversely affect Amgen’s operations.

2. Business Risks: Any failure to develop or acquire new products could reduce or limit future revenues, or the loss of key personnel could cause a drop in operational efficiency.

3. Competitive Risks: The biopharmaceutical industry is highly competitive, and Amgen’s competitors may be able to create more innovative biopharmaceutical products or gain access to lower-cost manufacturing facilities.

4. Financial Risk: Amgen’s financial performance depends on the pricing and reimbursement terms established by third-party payers, such as private and governmental health plans. Changes in payment or reimbursement terms could significantly affect Amgen’s results of operations.

5. Intellectual Property Risks: Amgen's success depends in part on its ability to protect its proprietary data, cardiopulmonary biomarkers, and biotechnology and pharmaceuticals inventions. Failure to obtain, maintain, and enforce its intellectual property rights could reduce Amgen’s revenues and increase its costs.

6. Litigation Risk: Amgen is subject to litigation related to many matters, including patent litigation, intellectual property litigation, product liability actions, and government investigations. The outcomes of these and other matters could significantly affect Amgen’s financial performance.